European Journal of Oncology Pharmacy最新文献

{"title":"Chemotherapy supply chain safety: current data from public oncology centers in Morocco","authors":"A. Ouasrhir, R. Rahhali, N. Boukhatem","doi":"10.1097/OP9.0000000000000014","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000014","url":null,"abstract":"Introduction: Since 2006, Morocco has been involved in care development for cancer patients, through regionalization of oncology centers, setting up of a program for cancer prevention, control, and treatment, finally by ensuring the quality of treatment. Chemotherapy is a risk-complexed process because of involving many health professionals. Our objective is to focus on the current state of public oncology hospitals and evaluate the chemotherapy process. Methods:An anonymous questionnaire was sent to 12 public centers by e-mails. It contains 4 items that establish chemotherapy process starting by receiving and storage of anticancer drugs, pharmaceutical validation of therapeutic protocols, until the administration of chemotherapy as well as the management of medical waste and expired medications. Results: Results showed that public regional centers represent 58.4% of participating centers, and university hospital centers represent 41.6%. Three quarters (73.3%) of hospital pharmacies have enough and appropriate receiving space. Sixty percent of pharmacist did not do any training to receive anticancer drugs. Oncology treatment protocols received in 53.3% of hospitals are not computerized. Biological data for pharmaceutical validation are not available on chemotherapy protocol in 73% of cases. All participating centers in the study confirmed that they have subcontracting contracts with companies specialized in the management of expired anticancer drugs and chemotherapy waste. Conclusion:Our study has shown that much effort has been made concerning the provision of oncology centers in several regions of the kingdom, anticancer drugs compounding centralization, and establishment-quality procedures that accompanied the chemotherapy process.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47063854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient satisfaction with information on chemotherapy","authors":"P. Oosterhof, Melissa Sombroek, M. Crul","doi":"10.1097/OP9.0000000000000015","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000015","url":null,"abstract":"","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45801300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality control of cytotoxic infusions disturbed by a change of infusion bag","authors":"P. Quinio, Benoît Beiler, P. Lider, B. Demoré, J. Vigneron","doi":"10.1097/OP9.0000000000000016","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000016","url":null,"abstract":"Introduction: In our centralized unit for the preparation of anticancer drugs, quality control is carried out by flow injection analysis (FIA) with detection by photodiode array detector. Criteria of concentration acceptance were established with ±10% of the theoretical concentration. The infusions were prepared with polyolefin infusions bags (Easyflex). However, due to an Easyflex shortage, Viaflo infusion bags were used and cyclophosphamide (CPM) concentrations showed a 10% increase despite a similar manufacturing process. The objectives of this work were to study the influence of different containers on CPM concentrations measured by FIA and to investigate the origin of this artificial increase in concentration. Methods: Thirty infusions were prepared using 3 different infusion bags: Viaflo multilayer container, Ecoflac, low-density polyethylene, and Easyflex polyolefin bags. Vials of CPM 1g were reconstituted with 50mL of 0.9% sodium chloride. CPM was injected into 0.9% sodium chloride 250-mL infusion bags. Then 1mL samples were withdrawn to be analyzed by FIA, to determine CPM concentrations (ultraviolet detection at 205nm). Results: Mean CPM concentration values (n=10) were 3.52mg/mL for Viaflo infusions, 3.12mg/mL for Ecoflac infusions, and 3.16mg/mL for Easyflex infusions. CPM concentrations were higher in Viaflo infusion bags. This difference could be explained by e-caprolactam, a component released by the multilayer infusion bag. Conclusion: Viaflo infusion bags disturb outcomes of CPM dosage with a concentration artificially increased by about 10%. The FIA method cannot be used to quantify CPM at this concentration and at wavelength 205nm. Abbreviations: CPM = cyclophosphamide; FIA = flow injection analysis; HDPE = high-density polyethylene; HPLC = highperformance liquid chromatography; LDPE = low-density polyethylene; PDA = photodiode array; RP-HPLC = reversed-phase highperformance liquid chromatography; UV = ultraviolet.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49624163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmaceutical consultations in oncology: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique – SFPO) guidelines","authors":"Emilie Petit-Jean, F. Correard, G. Maillan, F. D. Crozals, Benjamin Bertrand, V. Regnier, R. Chevrier, C. Streicher, I. Madelaine, B. Pourroy","doi":"10.1097/OP9.0000000000000011","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000011","url":null,"abstract":"","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42532732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stability studies in oncology","authors":"J. Vigneron, E. D’huart, B. Demoré","doi":"10.1097/OP9.0000000000000012","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000012","url":null,"abstract":"Introduction:Hospital pharmacists, physicians, and nurses need stability information on the drugs used in their daily practice. The objectives of this work were to evaluate if the information given by pharmaceutical companies about the stability of reconstituted and diluted solutions in the field of oncology were sufficient in the daily practice of hospitals. Methods: The first step was to establish a list of the main needs about stability data on the basis of the daily practice of hospital pharmacists. The second step was to search through information given by pharmaceutical companies and then to compare to hospital pharmacists’ needs. The third stepwas to find information in the cases, in which pharmaceutical companies’ informationwas not sufficient. Results: The situation is different depending on the product. For originators, stability data given by pharmaceutical companies are often very limited, the goal being to obtain the marketing authorization. For generics or biosimilars, extended stability studies are carried out to conquer the market and are part of the marketing strategy. A list of studies to fill the gap of companies’ information was presented. Examples including bortezomib, rituximab, azacitidine, nivolumab, and some mixtures were presented. The importance of stability studies conducted in hospitals is emphasized. Conclusion: Pharmaceutical companies perform stability studies for their products and for their own interest. In many cases, the results of these studies are insufficient and do not meet the need for information that hospital pharmacists are looking for. Conducting stability studies by hospital pharmacy teams should be encouraged. Abbreviation: SmPC = Summary of Product Characteristics.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45555284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of breast cancer treatment outcome at Tikur Anbessa Specialized Hospital Adult Oncology Unit, Addis Ababa, Ethiopia","authors":"Selamawit Dagne","doi":"10.1097/OP9.0000000000000013","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000013","url":null,"abstract":"The Department of Pharmacology and Clinical Pharmacy \u0000Presented in Partial Fulfillment of the Requirements for the Degree of Master of Pharmacy in Pharmacy Practice","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48394889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synadenium umbellatum and the Ehrlich's solid tumor treatment: Assessment of inflammatory regulators (transforming growth factor protein-&bgr;1 and tumor necrosis factor-&agr;) gene expression, hepatotoxicity and myelotoxicity","authors":"E. B. da Silva, Camila S. Chagas, Alexandre L. A. Fonseca, B. Alves, I. Bagatin, F. Perazzo, P. Rosa, D. Feder, F. Fonseca","doi":"10.1097/OP9.0000000000000009","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000009","url":null,"abstract":"Introduction: Studies have been attributed to cancer treatment, including the potential of several plants with putative anticancer activity. Among these is “Cola-note” (Synadenium umbellatum). Methods: We evaluated the effects of macerated S umbellatum at a concentration of 10 mg/kg in Bagg albino strain c mice and its myelotoxic, hepatotoxic, and antitumor activity as well as the expression of inflammatory genes (TGF-&bgr;1 and TNF-&agr;). Cells from Ehrlich tumor were implanted in the dorsolateral region of 8 mice of the Bagg albino strain c mice; these animals were divided into control (treated with NaCl 0.9%) and treatment group (treated with macerated Cola-Nota 10 mg/kg). Results: Treatment group animals showed no hepatotoxicity, but a potential myelotoxicity. The results suggest that treatment with Cola-Note macerate causes a decrease in expression of TNF-&agr; and an increased expression of TGF-&bgr;1. Discussion: The S umbellatum (10 mg/kg) is shown to be effective in reducing the concentration of neoplastic cachexia, but there was no antitumor activity.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61743744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of outpatient pharmacy services collaborating with oncologists at an outpatient clinic for outpatient chemotherapy prescription orders","authors":"K. Demachi, Shinya Suzuki, Hayato Kamata, Hidetaka Suzuki, Yuka Sugama, K. Ikegawa, T. Igarashi, T. Kawasaki, Philip E. Johnson, M. Yamaguchi","doi":"10.1097/OP9.0000000000000010","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000010","url":null,"abstract":"Objectives: This retrospective study was conducted to evaluate the impact of a service in which clinical pharmacists collaborated with oncologists at an outpatient clinic on chemotherapy order prescriptions and adverse drug reaction management in outpatient cancer chemotherapy. Methods: This was a single-center retrospective cohort study. Subjects were patients who received pharmacist services at an outpatient clinic in 6 treatment divisions at the National Cancer Center Hospital East from June to September 2016. Pharmacist interventions were categorized and assessed for impact by 2 pharmacists according to previously published methods. Results: The 6 pharmacists worked a total of 1396 hours, providing 1645 pharmacy interventions to 3419 patients. Of the 1645 interventions, 459 interventions (27.9%) involved chemotherapy order prescriptions. The 459 interventions for chemotherapy prescriptions were categorized according to the previously reported categories “drug therapy safety” (n = 330, 71.9%), “other” (n = 91, 19.8%), “drug therapy efficacy” (n = 28, 6.1%), and “drug therapy indication” (n = 10, 2.2%). Of the 91 interventions categorized as “other,” the 2 most frequent types of interventions were “confirmation from pharmacists to oncologists about laboratory test order” (n = 54, 11.7%) and “consultation from oncologists to pharmacists about chemotherapy regimen” (n = 23, 5.0%). Most interventions were identified as having “no error” (n = 369, 80.4%), while 8 interventions (1.8%) were identified as being “potentially lethal” or “serious.” Moreover, 92.8% of interventions were identified as being “extremely significant,” “very significant” or “significant.” Conclusions: This study clarified the benefits of outpatient pharmacy services in which pharmacists collaborate with oncologists at an outpatient clinic on outpatient chemotherapy prescription orders.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61743757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment options for patients with mantle cell lymphoma post-transplantation: A scoping review of the literature","authors":"E. Cowley, Thomas McFarlane","doi":"10.1097/OP9.0000000000000006","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000006","url":null,"abstract":"Abstract Mantle cell lymphoma is a rare subtype of B-cell lymphoma which carries with it a poor prognosis and is typically refractory to treatment. Autologous stem cell transplant (ASCT) has been shown to improve survival, but is not considered curative. There is currently no specific preferred regimen of treatment according to current guidelines for patients who fail ASCT. We undertook a systematic scoping review to examine the existing literature in this setting. A total of 3045 records were screened, yielding 40 full-text articles, 12 of which were included in the results. Ibrutinib and venetoclax appeared to produce the highest response rates and length of progression-free survival post-ASCT, however, there are serious gaps in the literature regarding what is actually known about the efficacy of treatment regiments for relapsed/refractory mantle cell lymphoma in post-ASCT patients and more randomized, controlled clinical trials are needed in this area.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43426650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ESOP PROFILE","authors":"","doi":"10.1097/01.op9.0000546428.56147.06","DOIUrl":"https://doi.org/10.1097/01.op9.0000546428.56147.06","url":null,"abstract":"","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43938506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}